Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 18/20 | 0.58 |
| ▸ | NOS3 | P29474 | 14/20 | 0.58 |
| ▸ | NOS2 | P35228 | 10/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074878 | 0.83 | NOS1 (0.42) | NOS1NOS3NOS2 | |
| SCHEMBL2745007 | 0.83 | HTR1D (0.41) | NOS1NOS3NOS2HTR1DHTR1B | |
| SCHEMBL221381 | 0.82 | NOS1 (0.84) | NOS1NOS3NOS2 | |
| SCHEMBL6585159 | 0.80 | NOS1 (0.59) | NOS1NOS3NOS2 | |
| SCHEMBL251335 | 0.80 | NOS1 (0.67) | NOS1NOS3NOS2 | |
| SCHEMBL7078300 | 0.79 | NOS1 (0.38) | NOS1NOS3NOS2 | |
| SCHEMBL6584246 | 0.78 | NOS1 (0.59) | NOS1NOS3NOS2 | |
| SCHEMBL421926 | 0.78 | NOS1 (0.56) | NOS1NOS3NOS2 | |
| SCHEMBL221285 | 0.77 | NOS1 (0.75) | NOS1NOS3NOS2 | |
| SCHEMBL8082378 | 0.77 | NOS1 (0.57) | NOS1NOS3NOS2HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3152220-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-12 | — | — | EP | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015186114-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015186068-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | GLAXOSMITHKLINE LLC (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2006094246-A2 | N-ARYLMETHYL BENZAMIDE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094237-A2 | ACRIDINE AND QUINOLINE DERVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094236-A1 | N-PHENYL BENZAMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094210-A2 | TETRAHYDROQUINOXALINONE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094248-A1 | ARYL-SUBSTITUTED CYCLIC SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094235-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006078941-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006076681-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | NOS1 1659/4885NOS3 1327/4885NOS2 1778/4885 |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | NNT, HADHB, NAMPT | NOS1 1911/4885NOS3 2462/4885NOS2 2495/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | NOS1 110/4885NOS3 157/4885NOS2 192/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | NOS1 1/4885NOS3 4/4885NOS2 3/4885 |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRT1, NAMPT, SIRT2 | NOS1 156/4885NOS3 243/4885NOS2 217/4885 |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | NNT, HADHB, NAMPT | NOS1 1911/4885NOS3 2462/4885NOS2 2495/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | NOS1 1659/4885NOS3 1327/4885NOS2 1778/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | NOS1 2484/4885NOS3 2496/4885NOS2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.